Revvity, Inc. (RVTY)
NYSE · Healthcare · Diagnostics & Research
$157.36+3.85%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $17.6B
- P/E (trailing)
- 75.3
- Forward P/E
- 26.7
- Dividend yield
- 0.2%
- 52-week range
- $81.22 – $158.28
- 52-week change
- +62.27%
- EPS (trailing)
- $2.09
- Analyst rating
- 2.5 Buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $2.9B (+3.67%)
- Net income
- $241M
- Operating margin
- 12.5%
- Diluted EPS
- $2.07
- Free cash flow
- $509M
From the company’s annual report on SEC EDGAR.
About Revvity, Inc.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery.
Headquarters: Waltham, United States · 11,000 employees · revvity.com